Selected Highlights from the 9th International Workshop on Clinical Pharmacology of HIV Therapy

HIV and AIDS Main Section
FDA-approved Treatments Experimental Treatments Top New Articles

The 9th International Workshop on Clinical Pharmacology of HIV Therapy
took place April 7 - 9, 2008 in New Orleans, LA. Pharmacological factors are an important cause of therapeutic failure during antiretroviral treatment. Inadequate exposure of HIV to drugs may be caused by non-adherence, drug interactions and variations in drug pharmacokinetics due to a variety of genetic and drug-specific characteristics.

The Workshop on clinical pharmacology in New Orleans provided an update on various topics, including newly detected drug-drug interactions, drug-induced toxicity, pharmacokinetics of investigational agents, generic drug use in resource-poor countries, and post-marketing surveillance projects. The workshop also presented the current state of the art on predicting drug interactions, designing drug interaction studies, and performing therapeutic drug monitoring (TDM).

This edition of HIV and Hepatitis.com focuses on the data presented on the pharmacokinetics of the new (FDA-approved) protease inhibitor darunavir (Prezista), the FDA-approved next generation NNRTI etravirine (Intelence), and the experimental next generation NNRTI TMC278.

Prezista (darunavir)

Pharmacokinetic-pharmacodynamic analyses of once-daily darunavir in the
ARTEMIS study
V Sekar and others.

Cocktail study to investigate the in-vivo drug interaction potential of darunavir coadministered with low-dose ritonavir (DRV/r; RTV) on cytochrome P450 enzymes 2D6, 2C9 and 2C19
V Sekar and others.

Effect of extrinsic and intrinsic factors on the pharmacokinetics of darunavir/ritonavir in HIV-1-infected patients: results of a randomized, controlled, Phase III study (ARTEMIS)
V Sekar and others.

Pharmacokinetic Profile of Darunavir (DRV) Co-Administered With Low-Dose Ritonavir (DRV/r) in Treatment-Experienced Women and Men With HIV Infection: 4-Week Analysis in a Substudy of the GRACE (Gender, Race, and Clinical Experience) Study.
V Sekar and others.

Effect of extrinsic and intrinsic factors on the pharmacokinetics of darunavir/ritonavir in HIV-1-infected patients: results of a randomized, controlled, Phase III study (ARTEMIS)
V Sekar and others.

The pharmacokinetic (PK) profile of darunavir with low-dose retonavir (DRV/r) in various multiple-dose regimens over 12 hours
M Boffito and others.

Pharmacokinetic-pharmacodynamic analyses of once-daily darunavir in the ARTEMIS study
V Sekar and others.

Intelence (etravirine)

No clinically relevant effect of etravirine (ETR; TMC125) on digoxin pharmacokinetics in HIV-negative volunteers
M Schöller-Gyüre and others.

TMC278

The effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral (ARV)-naïve HIV-1-infected patients
R Heeswijk and others.

4/18/08

Source
Tibotec Therapeutics